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Abstract
Matrix remodeling of cells is highly regulated by proteases and their inhibitors. Neverthe-
less, how would the chondrogenesis of mesenchymal stem cells (MSCs) be affected, when
the balance of the matrix remodeling is disturbed by inhibiting matrix proteases, is incom-
pletely known. Using a previously developed collagen microencapsulation platform, we
investigated whether exposing chondrogenically differentiating MSCs to intracellular and
extracellular protease inhibitors will affect the extracellular matrix remodeling and hence the
outcomes of chondrogenesis. Results showed that inhibition of matrix proteases particularly
the extracellular ones favors the phenotype of fibrocartilage rather than hyaline cartilage in
chondrogenically differentiating hMSCs by upregulating type I collagen protein deposition
and type II collagen gene expression without significantly altering the hypertrophic markers
at gene level. This study suggests the potential of manipulating extracellular proteases to
alter the outcomes of hMSC chondrogenesis, contributing to future development of differen-
tiation protocols for fibrocartilage tissues for intervertebral disc and meniscus tissue
engineering.
Introduction
The process of chondrogenesis occurs in stages beginning with mesenchymal cell condensation
followed by chondrocyte differentiation and maturation [1]. This process is characterized by a
series of differentiation stages with extracellular matrix (ECM) remodeling. In particular, the
stage-specific changes of pre-cartilaginous ECM containing fibronectin and type I collagen to car-
tilaginous ECM containing type II collagen and aggrecan as chondrocytic cells differentiate [2],
and then to a matrix rich in type X collagen during terminal differentiation of chondrocytes [1].
Matrix remodeling involving degradation of the old ECM and deposition of the new ECM is
important for tissue dynamic processes such as development, homeostasis and wound healing.
The process is highly regulated by proteases and their inhibitors [3]. Transgenic mouse model
PLOSONE | DOI:10.1371/journal.pone.0146928 January 13, 2016 1 / 14
a11111
OPEN ACCESS
Citation: Han S, Li YY, Chan BP (2016) Extracellular
Protease Inhibition Alters the Phenotype of
Chondrogenically Differentiating Human
Mesenchymal Stem Cells (MSCs) in 3D Collagen
Microspheres. PLoS ONE 11(1): e0146928.
doi:10.1371/journal.pone.0146928
Editor: Dmitry I Nurminsky, University of Maryland
School of Medicine, UNITED STATES
Received: July 22, 2015
Accepted: December 22, 2015
Published: January 13, 2016
Copyright: © 2016 Han et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by a grant from
The University of Hong Kong Small Project Funding
(201109176132), a Hong Kong Research Grants
Council General Research Fund award (17100714)
and a Hong Kong Innovation and Technology
Commission Grant (ITS/081/14FP). The funders had
no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
suggested that the loss of membrane-type 1 MMP proteolytic activity in unmineralized carti-
lage affects skeletal development by impairing collagen remodeling [4,5]. Moreover, matrix
metalloprotease-2 (MMP-2) regulated mesenchymal cell condensation by modulating the
fibronectin matrix [6]. These studies suggest that processes involving matrix remodeling such
as cell differentiation may be able to be manipulated by interfering with the balance of matrix
degradation.
We previously developed a collagen microencapsulation platform where mesenchymal stem
cells (MSCs) are entrapped in a reconstituted nanofibrous meshwork of type I collagen [7].
This type I collagen meshwork provides a good pre-cartilageous matrix template for the MSC
to remodel during chondrogensis, via simultaneous deposition of new cartilageous matrix rich
in type II collagen and proteoglycans, and degradation of the old type I collagen matrix [8,9].
This provides a good in vitro model to study the chondrogenesis process.
In the current study, we hypothesize that treatment of intracellular and extracellular prote-
ase inhibitors will affect the matrix remodeling of MSC during chondrogenesis. The signifi-
cance of this study is to manipulate the outcome of MSC chondrogenesis by modulating the
matrix degradation, so as to contribute to cartilage tissue engineering.
Materials andmethods
Culture of human mesenchymal stem cells (hMSCs)
Human MSCs from bone marrow [10] were kindly provided by Dr. G.C.F. Chan, Department
of Paediatrics and Adolescent Medicine, The University of Hong Kong and cultured as mono-
layers as previously described [10], according to a protocol approved by the Combined Clinical
Ethics Committee of the University of Hong Kong and Hong Kong West Cluster Hospitals of
Hospital Authority. In brief, hMSCs were cultured in growth medium (Dulbecco’s modified
Eagle’s medium-low glucose (DMEM-LG), 10% fetal bovine serum (FBS), 100 U/ml penicillin,
100 mg/ml streptomycin and 2 mM L-glutamine) at 37°C in a humidified atmosphere with 5%
CO2. The growth medium was replaced every 3–4 days. At around 80% confluence, hMSCs
were isolated by trypsinization with trypsin-EDTA (0.05%) briefly before re-suspending in full
medium for subsequent experiments. Cells at P6 were used for subsequent experiments.
Encapsulation of hMSCs into type I collagen scaffold
Human mesenchymal stem cells (hMSCs) at passage 6 were used for the subsequent experi-
ments. When hMSCs were ~80% confluent, cells were prepared for encapsulation into collagen
scaffold as described previously [7]. Briefly, cells were trysinized with 0.05% trypsin-EDTA.
Cell suspension were mixed with neutralized rat tail type I collagen solution obtained from
commercial source (BD Biosciences, Bedford, MA) [7] in an ice-bath with two parameters of
cell seeding density (4 x 106 cells/ml) and collagen concentration (1 mg/ml). Droplets of the
mixtures of various volumes (100 μl) were pipetted into petri-dishes with UV-irradiated paraf-
ilm covering the bottom of each dish, to prevent adhesion of the constructs to the substratum.
The collagen—hMSC mixtures were gelated when incubated at 37°C in a humidified atmo-
sphere with 5% CO2 for 45 min. The gelated droplets were then free-floated in growth medium
to allow contraction for 3 days. At day 3 after encapsulating hMSCs into collagen micro-
spheres, microspheres were moved into 24-well dishes covered with parafilm.
Chondrogenic differentiation of hMSC in collagen microspheres
Chondrogenic differentiation of hMSC-collagen microspheres was induced in the absence of
serum using the well-established culture condition [11] by replacing culture medium with
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chondrogenic differentiation induction medium (CM) at the third day after encapsulation. CM
was defined as Dulbecco’s modified Eagle’s medium-high glucose (DMEM-HG), supple-
mented with 10 ng/ml recombinant human TGF-β3 (Merck, Darmstadt, Germany), 100 nM
dexamethasone (Sigma, St. Louis, MO, USA), 0.1 mM L-ascorbic acid 2-phosphate (Fluka,
St. Louis, MO, USA), 6 mg/ml insulin (Merck), 6 mg/ml transferrin (Sigma), 1 mM sodium
pyruvate (Gibco, Grand Island, NY, USA), 0.35 mM L-proline (Merck), 100 U/ml penicillin,
100 μg/ml streptomycin and 2 mM L-glutamine) and 1.25 mg/ml bovine serum albumin (BSA)
(Sigma). CM was freshly prepared and regularly changed every 2 days for 4 weeks.
Intracellular and extracellular protease inhibition
At the day 0 of chondrogenic differentiation induction, hMSC-collagen microspheres were
divided in inhibitor treatment groups. Microspheres were maintained in CM for 28 days; each
group treated with protease inhibitors at an optimal concentration previously determined: E-
64D (Aloxistatin, Cayman chemical, 20mM) and/or GM6001 (Ilomastat, Millipore, 25mM).
Inhibitor stock solutions were prepared with DMSO at the concentration of 1mg/ml. One con-
trol group was treated with DMSO alone to check the effect of DMSO. The medium with inhib-
itors was freshly prepared and changed three times a week.
Histological, immunohistochemical (IHC), and immunofluorescence (IF)
analyses
Samples were fixed at desired time points with 4% PBS-buffered paraformaldehyde for 10 min
at room temperature and cut into frozen sections (12 μm) and paraffin sections (5 μm). The
sections were stained with hematoxylin and eosin (H&E) for histological analyses, or stained
with Alcian blue to visualize any glycosaminoglycan (GAG) deposit. The sections were per-
meabilized with 0.02% TritonX-100 for 10 min and depending on antigen, antigens were
retrieved by pepsin or hyaluronidase and pronase, then endogenous peroxidase activity was
blocked with H2O2. Sections were blocked with 2% normal horse serum for non-specific bind-
ing and then incubated with primary antibody against type I collagen, type II collagen, type X
collagen, Sox9, and aggrecan overnight at 4°C. Secondary antibody and avidin—biotin—perox-
idase complex (Vector Laboratories) with DAB substrate system (Dako) were used according
to the suppliers’ instructions. The sections were counterstained in hematoxylin. Negative con-
trol was performed without primary antibodies under identical conditions. Table 1 shows the
antibody dilution ratio for IHC.
For immunofluorescent analysis, after overnight incubation with primary antibodies at 4°C,
sections were further incubated with Alexa fluor-488, 546, 647 conjugated secondary antibody
in dark for 1 h at room temperature. Sections were mounted with anti-fading fluorescent
mounting medium with DAPI (Electron Microscopy Sciences, Hatfield, PA, USA). Table 2
shows the antibody dilution ratio for IF.
Table 1. The antibody dilution ratio for IHC.
Antibody Primary Secondary
Type I Collagen (Sigma Aldrich, c2456) 10000 2000
Type II collagen (Calbiochem) 1000 200
Type X collagen(ab58632, ab49945) 500 200
Aggrecan(ab3778) 1000/500 200/200
SOX9 (sc20095) 500 200
SOX9 (ab76997) 1000 200
doi:10.1371/journal.pone.0146928.t001
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Measurement of GAG content
The microspheres were digested overnight with 300 μg/ml papain in 50 mM phosphate buffer
(pH 6.5), containing 5 mM cysteine and 5 mM EDTA at 60°C. The amount of GAG accumula-
tion in the microspheres was determined by the 1, 9-dimethylmethylene blue (DMMB) method
[12]. GAG concentration was calculated by calibrating against a standard curve obtained with
shark chondroitin sulfate (Sigma). To assess the biosynthetic activity of the cells, results of GAG
quantification were normalized to the total protein represented by HYP or DNA content, which
was quantified by a fluorometric assay with Hoechst 33258 [13]. The DNA content was deter-
mined against a standard curve of calf thymus DNA (Sigma). Both the GAG and the DNA
assays were run in triplicate for each group. Data were expressed as mean ± standard deviation.
Hydroxproline (HYP) assay
To determine the content of HYP, which is the marker for collagen, 2 to 3 microspheres were
digested in a 100 μl digestion solution (pH 6.5) consisting of 50 mM phosphate buffer (Sigma),
5 mM EDTA (Sigma), 5 mM L-cysteine (Sigma), and 300 μg/ml papain (Sigma) at 60°C over-
night, as described previously [9]. Then a digested sample was hydrolyzed with 6 N HCl at
110°C for 18 h in a hydrolysis tube (Pierre) after being flushed with nitrogen gas for 30 s and
was neutralized by 6 N NaOH (pH 6~7). Neutralized samples were incubated with 50 μl of 0.05
M chloramine T solution (Sigma) for 20 min and oxidized by 50 μl of 3.15M perchloric acid
(Sigma) for 5 min and finally mixed with 50 μl p-dimethylaminobenzaldehyde (20%, w/v;
Sigma) for 20 min at 60°C for color development. The optical densities were measured at 557
nm with SaFire (TECAN) microplate reader. HYP content was estimated by linear interpola-
tion using trans-4-hydroxy-L-proline (Sigma) as standard.
Type II collagen ELISA
Type II collagen ELISA (Chondrex) was used to determine the amount of human type II colla-
gen in microspheres produced by hMSCs according to manufacturer’s instruction. Samples
were digested by pepsin in 0.5 N acetic acid with ratio of collagen:pepsin = 10:1 (w/w) for 7
days at 4°C. Supernatant was separated from insoluble residues by centrifugation at 15000 rpm
for 15 min. Then samples and standards were placed in 96-well plate pre-coated with capture
antibodies (details in manufacturer’s instruction) and detection antibody was added. The plate
was incubated for 2 h at room temperature and then washed and incubated with streptavidin
peroxidase for 1 h. The plate was washed and OPD solution was added for 30 min at room tem-
perature. Reaction was stopped by 2 N sulfuric acid and the amount of type II collagen was
measured by absorbance at 490 nm. Samples were running in quadruplicates.
Table 2. The antibody dilution ratio for IF.
Antibody Primary Secondary
Type I Collagen (Sigma Aldrich, c2456) 400 200
Type II collagen (Calbiochem) 100 400
Type X collagen (ab58632, ab49945) 100 200
Aggrecan(ab3778) 100 200
Aggrecan(sc25674) 100 400
SOX9 (sc20095) 50 400
SOX9 (ab76997) 100 400
MMP2(sc8835) 100 200
doi:10.1371/journal.pone.0146928.t002
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RNA isolation and quantitative real time-PCR
Total RNA was extracted using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH)
according to the manufacturer’s instructions. RNA was quantified using a NanoDrop-2000
spectrophotometer (NanoDrop, Rockland, DE) and was transcribed into cDNA using a Taq-
Man Reverse Transcription kit (Applied Biosystems, Foster City, CA). Gene expression levels
of collagen type I (COL1A2), aggrecan (ACAN), SRY (sex-determining region Y)-box 9
(SOX9), matrix metalloproteinase-13 (MMP-13), matrix metalloproteinase-2 (MMP-2) and
housekeeping gene eukaryotic 18s rRNA were determined by an ABI StepOne Plus real-time
PCR system using TaqMan1 Gene Expression Master Mix (Applied Biosystems) using stan-
dard thermal conditions. Assay IDs and Reference Sequence database accession numbers are
listed in Table below. Power SYBR1 Green PCRMaster Mix (Applied Biosystems) was used
for detection of collagen type II (COL2A1), collagen type X (COL10A1) using glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) as the housekeeping gene. The sequences of primers
used in real time PCR were listed in Tables 3 and 4.
Data presentation and statistics
Quantitative data on diameter of the microspheres, collagen content, GAG content, DNA con-
tent and expression level of various genes were presented as mean ± SEM. The normality
assumption was verified with the Kolmogorov-Smirnov test and the equal variance assumption
was verified by Levene’s test to justify the use of parametric tests. Data among different treat-
ment groups at different time points was compared using two-way ANOVA with appropriate
post-hoc tests. For data with equal variance assumed, Bonferroni’s test was used. For data with-
out equal variances, Dunnett’s T3 test was used. SPSS 19.0 was used to execute all analyses and
the statistical significance was set at α = 0.05.
Results
Collagen remodeling by encapsulated hMSCs with and without
chondrogenesis
Remodeling refers to simultaneous degradation and synthesis of extracellular matrices (Fig
1A–1H). In collagen encapsulated hMSCs without chondrogenesis induction, remodeling hap-
pens as soon as cell encapsulation starts, that is when cells start to interact with collagen gel,
degradation starts. Degradation was demonstrated by presence of fluorescence signals of DQ
collagen, which turns fluorescent when collagen is being degraded (Fig 1A). The degraded col-
lagen (green channel) was largely co-localizing with (Fig 1G) the fluorescence staining of the
rat type I collagen (Fig 1C), which refers to the starting material. The extracellular matrix is
being remodeled by hMSCs as simultaneous synthesis of human type I collagen was shown by
the intense immunofluorescence staining of human type I collagen at the intracellular space
(Fig 1B) and the slight extracellular deposition overlaying with both DQ collagen (Fig 1E) and
rat collagen (Fig 1F). During chondrogenesis of hMSC in the 3D collagen microspheres,
remodeling of the matrix was also demonstrated (Fig 1I–1N). Firstly, newly synthesized and
deposited human type II collagen was found (Fig 1J), it largely co-localized with (Fig 1K) the
immunofluorescent staining of rat type I collagen (Fig 1I), the starting material. Secondly,
Alexa488 fluorescence labeled rat type I collagen (Fig 1L) largely co-localized (Fig 1N) with
immunofluorescent staining of human type II collagen (Fig 1M) at certain regions particularly
pericellular and extracellular space, suggesting that chondrogenically differentiating hMSCs
used the rat collagen meshwork as the template or scaffold for deposition of new cartilage
matrices.
Protease Inhibition Affects hMSC Chondrogenesis
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Inhibiting intracellular and extracellular protease degradation
differentially affected chondrogenesis
Interfering with protease degradation, both intracellular and extracellular ones, reduced the
extent of encapsulation-based contraction of collagen by hMSCs (Fig 2A). Live/Dead staining
showed that the cell viability of hMSCs after chondrogenesis did not significantly vary among
different groups (Fig 2B1–2B5). Sox9 is an early chondrogenic marker and has been found
expressing in all groups (Fig 2C1–2C5) including the normal medium negative control, sug-
gesting that the collagen microencapsulation process alone (Fig 2C1) may induce hMSC chon-
drogenesis. Alcian blue staining showed the extracellular matrix glycosaminoglycan (GAG) in
the hMSCs-encapsulated microspheres (Fig 2D1–2D5) where intensive staining was found in
the chondrogenesis group with TGFbeta (positive control) (Fig 2D2) and the chondrogenesis
group in the presence of extracellular matrix protease inhibitor groups (Fig 2D4 and 2D5).
However, no GAG staining was found in the normal medium negative control group (Fig 2D1)
while a few GAG-rich nodules were found in the chondrogenesis group with the intracellular
protease inhibitor (Fig 2D3). Similar trend was found in the immunohistochemical staining of
the specific extracellular matrix marker of chondrogenesis type II collagen (Fig 2E1–2E5)
where positive staining was found in the chondrogenesis positive control group (Fig 2E2), as
well as those with the presence of extracellular protease inhibitors (Fig 2E4 and 2E5). No type
II collagen was identified in the negative control group (Fig 2E1) while a few nodules with posi-
tive type II collagen staining were identified in the intracellular protease inhibitor group (Fig
2E3). Aggrecan was only observed in the positive control group (Fig 2F2) but not other groups
(Fig 2F1, 2F3–2F5), suggesting that protease inhibition interfere with the aggrecan deposition.
Type I collagen was found in all groups (Fig 2G2–2G5) except negative control group (Fig 2F1)
while significantly more type I collagen was deposited in the groups with extracellular protease
inhibitors (Fig 2G4 and 2G5) than chondrogenesis group (Fig 2G2). The hypertrophy marker
type X collagen was found in all groups but expressed at a minimal intensity (Fig 2H1–2H5).
Table 3. The primer sequences of genes tested in real time-PCR analysis.
Gene Symbol Protein Product Assay ID / Primer sequence
ACAN Aggrecan Hs00153936_m1
SOX9 SRY (sex-determining region Y)-box 9 Hs00165814_m1
MMP13 Matrix Metalloproteinase-13 Hs00233992_m1
Col1A2 Type I collagen Hs00164099_m1
MMP2 Matrix Metalloproteinase-2 Hs01548727_m1
18S rRNA Ribosomal 18s rRNA X03205.1 (Accession Number)
doi:10.1371/journal.pone.0146928.t003
Table 4. The primer sequences for SYBR green real time-PCR assays.
Gene symbol Protein Product Primer sequence
Col2A1 Type II collagen Fw: 5’- TCACGTACACTGCCCTGAAG-3’
Rv: 5’- TGCAACGGATTGTGTTGTT-3’
Col10A1 Type X collagen Fw:5’-CAGATTTGAGCTATCAGACCAACAA-3’
Rv:5’-AAATTCAAGAGAGGCTTCACATACG-3’
GAPDH Glyceraldehyde 3-phosphate dehydrogenase Fw: 5’- GAGTCAACGGATTTGGTCGT-3’
Rv: 5’-TTGATTTTGGAGGGATCTCG-3’
doi:10.1371/journal.pone.0146928.t004
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Fig 1. Collagen remodeling in hMSC in rat collagenmicrospheres. (A-H) Collagen type I remodeling by microencapsulated-hMSCs after 24 hours of
incubation. Green: Bovine DQ FITC collagen type I 10 mg/ml, Orange: Human type I collagen, Red: Rat type I collagen 1 mg/ml and Blue: DAPI. (A)
Fluorescent staining of bovine DQ FITC type I collagen, which was mixed with rat type I collagen during fabrication of microspheres and it fluoresces if
degraded; (B) Immunofluorescent staining of human type I collagen, which should be synthesized by hMSC; (C) Immunofluorescent staining of rat type I
collagen; (D) DAPI, which labelled the nuclei; (E) Merged panels A+B+D (cell nuclei in degrading DQ collagen and newly synthesized human type I collage);
Protease Inhibition Affects hMSC Chondrogenesis
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Inhibiting protease degradation altered the ECM composition and
cellularity
Treating the chondrogenically differentiating hMSC-collagen microspheres with intracellular
and extracellular protease inhibitors resulted in very different extracellular matrix composi-
tions (Fig 3) (one-way ANOVA, p<0.001). Fig 3A showed the total collagen content in various
groups. When intracellular protease inhibitor ED64 alone was supplemented, there was a 50%
reduction in the HYP or total collagen content but the difference was not statistically signifi-
cant (Dunnet T3 posthoc test, p = 0.088). On the other hand, when extracellular protease
inhibitor GM6001 was supplemented, alone or in combination with ED64, there was dramatic
increase of almost 7 folds in the total collagen content (Dunnett T3 posthoc test, p = 0.037),
suggesting that there was a net collagen deposition. When both intracellular and extracellular
protease inhibitors were supplemented, the effects of the GM6001 dominated and the total col-
lagen content also increased for 7 folds (Dunnett T3 posthoc test, p = 0.033). Fig 3B showed
the type II collagen content in various groups but one-way ANOVA did not show any statisti-
cal significant difference (p = 0.063). The intracellular protease inhibitor reduced the collagen
type II content for about 50% while groups with extracellular protease inhibitor, either alone or
together with the intracellular protease inhibitor, showed similar type II collagen content as
that of the positive control (p0.986), corroborating with the immunohistochemistry results
in Fig 2E. The differential deposition between total collagen and type II collagen to extracellular
protease inhibitor suggested that the 7 fold of increase in total collagen content was not attrib-
utable to the Type II collagen, but likely to be type I collagen, as indicated by the immunohis-
tochemistry results in Fig 2G. Fig 3C showed the GAG content. All groups including the
intracellular and extracellular protease inhibitors have shown some reduction in GAG content
comparing with that of the positive control but the difference was not statistically significant
(one way ANOVA, p = 0.951). Fig 3D showed the DNA content. Oneway ANOVA showed no
significant difference among different groups (p = 0.091). Groups with the presence of extracel-
lular protease inhibitor showed some increase but the difference was not statistically significant
(p0.203).
Inhibiting protease degradation altered the gene expression of
chondrogenic markers of hMSCs during chondrogenic induction in
collagen microspheres
SOX9 is the master chondrogenesis transcription factor (Fig 4A). Oneway ANOVA showed
significant difference among various groups (p<0.001) but Dunnett T3 posthoc tests did not
reveal this difference as statistically significant (p0.104). COL2A1 is the most specific extra-
cellular matrix gene expression marker for chondrogenesis. There was significant difference
among different groups (Fig 4B) (Oneway ANOVA, p<0.001). Specifically, there was a dra-
matic increase of>15 fold in the COL2A1 gene expression when both ED and GM were pres-
ent (Bonferroni’s posthoc test, p<0.001), suggesting synergistic interactions of intracellular
and extracellular protease inhibitors. Nevertheless, the upregulated gene expression of
COL2A1 was not reflected in the immunohistochemistry staining in Fig 2E4 and ELISA in Fig
(F) Merged panels B+C+D (cell nuclei in starting material rat collagen and newly synthesized human type I collagen); (G) Merged panels A+C+D (starting
materials rat type I collagen and DQ collagen are largely co-localizing); (H) Merged panels A+B+C+D (cells synthesizing human type I collagen in starting
materials, which are undergoing degradation); (I-N) Collagen type II deposition in MSC-collagen type I microsphere after chondrogenic differentiation for 21
days; (I) Immunofluorescent staining of rat type I collagen, which is the starting material of the microsphere; (J) Immunohistochemistry of human type II
collagen (DAB: substrated), which is newly synthesized by MSC during chondrogenic differentiation; (K) Merged panels (I+J); (L) Alexa fluor 488 labelled rat
type I collagen; (M) Immunofluorescent staining of human type II collagen; (N) Merged panels (L+M) showing co-localization in some regions.
doi:10.1371/journal.pone.0146928.g001
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3B. Moreover, although ED alone increased for 2 folds and GM alone for 3.5 folds, the differ-
ences were not statistically significant (p0.53). Aggrecan is one major proteoglycans synthe-
sized during chondrogenesis although undifferentiating hMSCs have been shown to synthesize
aggrecan as well [14]. Oneway ANOVA showed significant difference in ACAN gene
Fig 2. HumanMSC-collagenmicrospheres under cultures. (A) Temporal change in the size of hMSC-
collagen microspheres (n = 10); (B1-5) Live and Dead staining of hMSCs in collagen microspheres at day 21
during chondrogenic differentiation (Green: Live cells labeled by cacein AM; Red: Dead cells labeled
ethidium homodimer-1); (C1-5) sox 9 immunofluorescence; (D1-5) Alcian blue staining; (E1-5) Type II
collagen immunohistochemistry; (F1-5) Aggrecan immunohistochemistry; (G1-5) Type I collagen
immunohistochemistry; (H1-5) Type X collagen immunohistochemistry; 1: Negative control (Normal
medium); 2: Positive control (Chondrogenic medium with TGFβ alone); 3: ED (Chondrogenic medium with
TGFβ and intracellular protease inhibitor E64D); 4: GM (Chondrogenic medium with TGFβ and extracellular
matrix protease inhibitor GM6001); 5: ED+GM (Chondrogenic medium with TGFβ and both intracellular
protease inhibitor E64D and extracellular protease inhibitor GM6001).
doi:10.1371/journal.pone.0146928.g002
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expression among different groups (Fig 4C) (Oneway ANOVA, p = 0.005). Comparing with
the chondrogenesis positive control, the aggrecan gene (ACAN) was significantly reduced in
the negative control (Dunnett T3 posthoc tests, p = 0.017), and the groups with the presence of
extracellular protease inhibitors (Dunnett T3 posthoc tests, p0.020). Type I collagen
(COL1A1) showed slightly reduced expression in groups treated with protease inhibitors (Fig
4D) but the difference was not statistically significant (Oneway ANOVA, p>0.05). Type X col-
lagen (COLX) and MMP13 are regarded as the hypertrophic markers, which are usually upre-
gulated when chondrocytes undergo terminal differentiation to hypertrophic chondrocytes.
There was no significant change in the COLX expression in groups with either intracellular or
Fig 3. Bar charts showing the extracellular matrix composition of hMSC-collagenmicrospheres after
chondrogenesis. (A) Hydroxyproline (collagen) content (n = 3); (B) Type II collagen content, measured
using ELISA (n = 4); (C) Glycosaminoglycan (GAG) content (n = 3); and (D) DNA content (cellularity) (n = 3).
doi:10.1371/journal.pone.0146928.g003
Fig 4. Bar charts showing the expression level of genes related to chondrogenesis. (A) SOX9 (gene of
sox9); (B) COL2A1 (gene of type II collagen); (C) ACAN (gene of aggrecan); (D) COL1A1 (gene of type I
collagen); (E) COLX (gene of type X collagen); (F) MMP13 (gene of matrix metalloprotease 13); (G) MMP2
(matrix metalloprotease 2 or gelatinase A) (n = 3 in triplicates).
doi:10.1371/journal.pone.0146928.g004
Protease Inhibition Affects hMSC Chondrogenesis
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extracellular protease inhibitor (Fig 4E) (Oneway ANOVA, p = 0.087). MMP13 is a matrix pro-
tease selectively digesting type II collagen and its expression is related to hypertrophy [15] and
cartilage degeneration [16]. Comparing with chondrogenesis positive control, all groups
including the protease inhibitor groups and the negative control all significantly down regu-
lated MMP13 expression (Fig 4F) (Oneway ANOVA, p<0.001, Bonferroni’s posthoc tests,
p0.016). Taking together the results of COLX and MMP13 expression, treating hMSCs dur-
ing chondrongenesis with protease inhibitors did not promote hypertrophy. MMP2 is gelati-
nase which digests collagen after activation by the action of membrane bound MMPs such as
MMP14 [17]. There was no significant difference in MMP2 expression in all groups (Fig 4G)
(Oneway ANOVA, p = 0.352).
Discussion
The current study demonstrates that inhibiting matrix proteases affects the outcomes of chon-
drogenic differentiation of human MSCs primarily through an enhanced collagen matrix depo-
sition. In our previous study, the collagen microencapsulation platform has been shown to be
chondroconductive that hMSCs entrapped in collagen microspheres were able to differentiate
towards the chondrogenic lineages by expressing chondrogenic markers and remodeling the
template type I collagen matrix meshwork with a cartilage-specific matrix rich in type II colla-
gen and aggrecan [9]. In the current study, we further demonstrate that hMSCs utilized the rat
tail type I collagen meshwork in the microsphere as the template for deposition of the new
human type II collagen matrix as shown by their co-localization. Extracellular matrix remodel-
ing is important in tissue dynamic states including development, homeostasis and regenera-
tion, it is therefore logical to hypothesize that manipulating the matrix remodeling process
through the inhibition of matrix proteases will affect the outcomes of chondrogenic differentia-
tion of hMSCs in this 3D platform.
Table 5 summarizes the overall effects of intracellular and extracellular protease inhibitors
on hMSC chondrogenesis. Inhibiting protease degradation in general reduces the gene expres-
sion of the major chondrogenic transcription factor SOX9 and this is particularly effective
when extracellular protease inhibitor was used although the sox 9 staining did not alter much.
Inhibiting the extracellular proteases showed a significant increase in the total collagen content
and the type I collagen staining although its gene expression did not alter much. On the other
hand, type II collagen gene expression is dramatically upregulated even though its protein
expression did not change significantly. Our in house data in separate study demonstrate that
exposing hMSC pellet culture to protease inhibitors in time result in enhanced expression of
type I and type II collagen, and aggrecan although GAG content was decreased (S1 Fig). These
changes suggest that hMSCs commit towards a fibrocartilage phenotype under the influence of
matrix protease inhibition during chondrognesis. Bertram et al. [18] found that broad spec-
trum pan-MMP inhibitors suppressed all chondrogenesis markers including SOX9, type II col-
lagen and proteoglycans while our study confirmed the reduction in sox9 and aggrecan gene
expression but showed enhanced type II collagen gene expression. This discrepancy may be
due to the difference in the in vitro chondrogenic models used. A spheroid model was used in
that study while the current model uses a collagen microsphere model. This suggests that the
presence of extracellular matrix in the 3D model might interfere with the responses of hMSC
to protease inhibitors. Previous studies have demonstrated that integrin binding is involved in
MSC chondrogenesis. For example, hMSCs encapsulated in hydrogel incorporated with colla-
gen mimetic peptide capable of binding cells via β1 integrins showed greater extent of chondro-
genic differentiation than in hydrogel alone [19]. Blockage of β1 integrin reduced gene
expression of chondrogenic markers by hMSCs encapsulated in hydrogel with type I collagen
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incorporation [20]. Mhanna et al. [21] also demonstrated that hydrogel modified with collagen
mimetic peptide favored GAG production and gene expression of type II collagen and aggre-
can, compared to hydrogel modified with fibronectin adhesion peptide. The current collagen
microencapsulation platform imposed high density collagen ligands and hence subsequent
binding and signaling to hMSCs during chondrogenesis that may help to promote collagen
deposition. A high type I collagen deposition is regarded as a typical feature in fibrocartilage
[22]. Fibrocartilage tissues such as annulus fibrosus and menisci are typically characterized by
high levels of type I collagen as well as the presence of proteoglycans [23]. A large variety of
biochemical and mechanical stimuli have been applied in fibrocartilage tissue engineering [24].
The potential of manipulating protease inhibitors to promote fibrocartilage formation for
intervertebral disc and meniscus tissue engineering needs to be further investigated.
It is interesting to note that manipulating collagen remodeling using protease inhibitors also
partially affects the proteglycan metabolism. Specifically, gene expression of the major cartilage
proteoglycan aggrecan was downregulated, although the protein expression and content was
not significantly changed. This suggests possible interactions between the collagen deposition
and proteoglycan regulation. It is generally known that collagen fibrillogenesis can be regulated
by proteoglycans particularly the small leucine-rich proteoglycans (SLRPs) including decorin,
aspirin and fibromodulin [25, 26]. Moreover, interactions of matrix metalloproteinases
(MMPs) for collagen and aggrecanases (e.g. ADMATSs) for aggrecans in regulating extracellu-
lar matrix remodeling have been suggested in musculoskeletal tissue pathology such as inter-
vertebral disc degeneration [27]. The crosstalk between collagen deposition upon protease
inhibition and proteoglycan expression warrants further investigation before targeting these
enzymes for promoting extracellular matrix deposition during tissue engineering.
Table 5. Summary on the gene and protein expression of chondrogenic markers in chondrogenically differentiating hMSCs in collagenmicro-
spheres under different protease inhibitor treatment.
Chondrogenic markers Treatment groups
Positive ED ED+GM GM
Sox 9 Sox 9 staining — — — —
SOX9 gene — # # ##
Total collagen HYP content — — "" ""
Col I Col I staining — # " "
Col I gene — — — —
Col II Col II staining — # — —
Col II ELISA — — — —
Col II gene — " "" "
Proteoglycan GAG staining — # — —
GAG content — — — —
Aggrecan staining — # — —
ACAN gene — — # #
Col X Col X gene — — — —
MMP13 MMP13 gene — # # #
MMP2 MMP2 gene — — — —
“—”denotes similar expression; “#” denotes downregulation; “##” denotes extensive downregulation; “"” denotes upregulation; “""” denotes intensive
upregulation.
doi:10.1371/journal.pone.0146928.t005
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Conclusions
The current study demonstrated that inhibition of extracellular proteases affects chondrogenic
differentiation of MSCs by favoring the phenotype of fibrocartilage with upregulated type I col-
lagen deposition and type II collagen gene expression, without obvious change in the gene
expression of the hypertrophy marker type X collagen. This study suggests the potential of
manipulating extracellular proteases to differentiate hMSCs towards fibrocartilage formation
in intervertebral disc and meniscus tissue engineering.
Supporting Information
S1 Fig. Human MSC pellet culture. A-E: Alcian blue staining of hMSC pellet culture at day
21; F-J: Dual channel immunofluorescent staining of type I collagen (green) and sox 9 (red);
K-O: Dual channel immunofluorescent staining of type II collagen (green) and aggrecan (red);
A, F, K: Normal medium; B, G, L: Chondrogenic medium; C, H, M: Chondrogenic medium
with intracellular protease inhibitor E64D; D, I, N: Chondrogenic medium with extracellular
matrix protease inhibitor GM6001; E, J, O: Chondrogenic medium with both E64D and
GM6001.
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